Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
Leukemia ; 16(4): 601-7, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11960339

ABSTRACT

The objective of this study was to identify biologic parameters that were associated with either exceptionally good or poor outcome in childhood acute myeloid leukemia (AML). Among the children with AML who entered Children's Cancer Group trial 213, 498 patients without Down syndrome or acute promyelocytic leukemia (APL) comprise the basis for this report. Univariate comparisons of the proportion of patients attaining complete remission after induction (CR) indicate that, at diagnosis, male gender, low platelet count (< or =20 000/microl), hepatomegaly, myelodysplastic syndrome (MDS), French-American- British (FAB) category M5, high (>15%) bone marrow (BM) blasts on day 14 of the first course of induction, and +8 are associated with lower CR rates, while abnormal 16 is associated with a higher CR rate. Multivariate analysis suggests high platelet count at diagnosis (>20 000/microl), absence of hepatomegaly, < or =15% day 14 BM blast percentage, and abnormal 16 are independent prognostic factors associated with better CR. Univariate analysis demonstrated a significant favorable relationship between platelet count at diagnosis (>20 000/microl), absence of hepatomegaly, low percentage of BM blasts (< or =15%), and abnormal 16 with overall survival. Absence of hepatomegaly, < or =15% day 14 BM blast percentage, and abnormal 16 were determined to be independent prognostic factors associated with better survival.


Subject(s)
Leukemia, Myeloid/diagnosis , Acute Disease , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Blood Cell Count , Bone Marrow/pathology , Bone Marrow Examination , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Karyotyping , Leukemia, Myeloid/drug therapy , Leukemia, Myeloid/mortality , Leukocyte Count , Male , Platelet Count , Prognosis , Remission Induction , Survival Rate
2.
Mayo Clin Proc ; 75(3): 303-9, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10725961

ABSTRACT

This article describes the historic experience of the development of antiemetic guidelines for patients taking chemotherapy drugs at Mayo Clinic Rochester. The initial guidelines for the use of serotonin (5-hydroxytryptamine3) receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting were developed in early 1995 and implemented in September 1995. In February 1997, the guidelines were reviewed and modified. In the spring of 1998, major changes were made based on new data from the literature and discussions with antiemetic authorities in the United States. These guidelines were implemented in July 1998. The guidelines were again reviewed and modified in December 1998. In addition, we compared costs associated with the 1997 guidelines and the December 1998 guidelines. The developed guidelines, utilizing clinically available agents, seem to provide high-quality patient care at a reasonable cost.


Subject(s)
Antiemetics/therapeutic use , Nausea/drug therapy , Vomiting/drug therapy , Antiemetics/economics , Antineoplastic Agents/adverse effects , Humans , Minnesota , Nausea/chemically induced , Patient Satisfaction , Practice Guidelines as Topic , United States , Vomiting/chemically induced
5.
J Clin Oncol ; 15(1): 76-84, 1997 Jan.
Article in English | MEDLINE | ID: mdl-8996127

ABSTRACT

PURPOSE: The specific aims of this study were to improve event-free survival (EFS) in patients with newly diagnosed nonmetastatic osteosarcoma of an extremity using the histologic response to neoadjuvant chemotherapy to determine postoperative chemotherapy; to evaluate a uniform histologic grading system that measures tumor response; and to identify patient characteristics that might influence EFS and survival. PATIENTS AND METHODS: Two hundred sixty-eight patients with nonmetastatic osteosarcoma of the extremity were entered between August 1983 and October 1986. Preoperative chemotherapy consisted of four courses of high-dose methotrexate (MTX) and one course of bleomycin, cyclophosphamide, and dactinomycin (BCD). Histologic response to preoperative chemotherapy was determined by morphometric analysis. Good histologic responders (< 5% residual viable tumor) were treated postoperatively with MTX, BCD, and doxorubicin (DOX); poor histologic responders were treated with BCD, DOX, and cisplatin (CDDP). RESULTS: The 8-year EFS and survival rates were 53% and 60%, respectively. Two hundred six patients had their tumors assessed for histologic response: 28% displayed a good histologic response to preoperative chemotherapy. Good histologic responders had an 8-year postoperative EFS rate of 81% and survival rate of 87%; those with a poor histologic response had an 8-year postoperative EFS rate of 46% and survival rate of 52%. A primary tumor site in the proximal humerus or proximal femur and an elevated serum alkaline phosphatase level were associated with an increased risk of an adverse event, whereas the type of surgical procedure was not. CONCLUSION: EFS and survival appear to be directly related to histologic response to neoadjuvant chemotherapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/drug therapy , Extremities , Osteosarcoma/drug therapy , Adolescent , Bleomycin/administration & dosage , Bone Neoplasms/pathology , Bone Neoplasms/surgery , Chemotherapy, Adjuvant , Child , Cyclophosphamide/administration & dosage , Dactinomycin/administration & dosage , Disease-Free Survival , Humans , Methotrexate/administration & dosage , Osteosarcoma/pathology , Osteosarcoma/surgery , Vincristine/administration & dosage
9.
J Pediatr Hematol Oncol ; 17(2): 172-5, 1995 May.
Article in English | MEDLINE | ID: mdl-7749769

ABSTRACT

PURPOSE: Dose reduction of chemotherapeutic agents in response to weight loss or amputation is important in avoiding excessive therapy-related toxicity. Several methods of calculating this dose reduction are currently in use, including dose reduction in proportion to (a) the reduction in body surface area (BSA), (b) the amount of weight lost, and (c) no dose reduction unless toxicity is observed. Each of these methods results in the administration of a different dose, and few guidelines exist as to the preferred method. METHODS: We conducted a survey of a large group of pediatric oncologists, pediatric oncology nurses, and data managers to determine the methods of dose reduction currently in use for patients (a) with weight loss, (b) after amputation, and (c) with further weight loss after amputation. RESULTS: Responses were obtained from 237 of 294 individuals surveyed (80.6%). The most popular method was to dose reduce in proportion to the reduction in BSA in patients with weight loss alone (88%), amputees (60%), and amputees with ongoing weight loss (66%). Other methods were chosen by 7%, 31%, and 24% of participants in each of these clinical settings, respectively. CONCLUSION: The chosen methods result in a discrepancy of administered doses of up to 37%. Our results highlight the need for the standardization of practice, and the determination of the optimal method of dose reduction after weight loss or amputation.


Subject(s)
Amputation, Surgical , Antineoplastic Agents/administration & dosage , Body Weight/physiology , Medical Oncology/methods , Professional Practice , Weight Loss , Body Surface Area , Child , Dose-Response Relationship, Drug , Humans , Practice Patterns, Physicians'
11.
J Pain Symptom Manage ; 9(4): 259-64, 1994 May.
Article in English | MEDLINE | ID: mdl-8089542

ABSTRACT

Procedure-related pain is a significant problem for many children receiving cytotoxic chemotherapy. In an effort to lessen this toxicity, we studied the efficacy and safety of administering topical local anesthesia using EMLA cream in 47 evaluable children with cancer undergoing implanted central venous port injections. Children (< 21 years old) scheduled to undergo repeated venous access procedures were selected for study. A placebo-controlled, randomized, double-blind, crossover study design was utilized. Statistically significant decreases in pain intensity scores (P < 0.002) were recorded by both children and investigators during the use of EMLA cream as compared with placebo. There was a good correlation between pain scores recorded by both patients and health care providers using both visual analog scales and categorized pain measurement tools. The topical application of EMLA cream 5% provides highly effective superficial anesthesia, and promises to be extremely useful for pain relief during percutaneous access procedures in cancer patients.


Subject(s)
Anesthetics, Local/administration & dosage , Injections, Intravenous/adverse effects , Lidocaine/administration & dosage , Neoplasms/drug therapy , Pain/prevention & control , Prilocaine/administration & dosage , Administration, Cutaneous , Adolescent , Adult , Antineoplastic Agents/administration & dosage , Child , Child, Preschool , Double-Blind Method , Drug Combinations , Female , Humans , Lidocaine, Prilocaine Drug Combination , Male , Neoplasms/complications , Ointments
19.
J Pediatr Surg ; 27(2): 155-63; discussion 163-4, 1992 Feb.
Article in English | MEDLINE | ID: mdl-1564612

ABSTRACT

This is an interval analysis of the 2-year prospective multicenter Childrens Cancer Study Group study of 1,141 chronic venous access devices in 1,019 children with cancer. Device type was external catheter (EC) 72%, totally implantable (TID) 28%, and did not differ for diagnosis or age except more double-lumen devices in bone marrow transplant protocols (77%) and more TIDs in children less than 1 year old (17.7%). Insertion characteristics evaluated in 1,078 (95%) were: operating room placement 99%; general anesthesia 98%; cutdown 67%; percutaneous 33%; atrial position 50%, caval position 50%; and perioperative antibiotics 48%. Vein entry was the external jugular 33%, internal jugular 22%, subclavian 35%, cephalic 7%, and saphenous 3%. Insertion was difficult or very difficult in only 10% and operative complications occurred in only 0.7%. Degree of difficulty bore no relationship to device type or patient age. The reasons for removal in 736 devices (67%) were due to complications in 39%, of which infections were the most frequent. There was some variance between centers ranging from 8.5% to 31% for infection; 2.8% to 24% for dislodgment; and 0% to 13% for occlusion. ECs had a higher risk of dislodgment; elective removals were more frequent in TIDs; there was no difference in infection as a cause for removal between ECs and TIDs. Dislodgment was associated with the shortest distance of the cuff to the skin exit (mean, 4 cm): less than or equal to 2 cm, 49%; greater than 2 cm, 28% (P = .009) and occurred most frequently in the younger patient (18.9%, 0 to 1 years; 0.5%, greater than 8 years.


Subject(s)
Catheterization, Central Venous/instrumentation , Catheters, Indwelling , Adolescent , Age Factors , Anesthesia, General , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Bacterial Infections/etiology , Catheterization, Central Venous/adverse effects , Catheterization, Central Venous/methods , Child , Child, Preschool , Equipment Design , Equipment Failure , Humans , Infant , Jugular Veins , Neoplasms/drug therapy , Prospective Studies , Registries , Subclavian Vein , Venous Cutdown
SELECTION OF CITATIONS
SEARCH DETAIL
...